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ABSTRACT
Unsustainable drug prices in chronic myeloid leukemia (CML) and cancer may be causing harm to patients. The aim of this multi-
center study is to assess the efficacy of generic imatinib mesylate (IM) over Glivec in terms of hematological, cytogenetic, and mo-
lecular responses in CML. The data of 120 CML patients, who were treated with generic or original form of IM, were obtained from 
six different hematology clinics in Turkey between the years of 2009-2014 and analyzed retrospectively. Initial evaluation revealed that 
only one patient who was using original molecule switched to second generation tyrosine kinase inhibitor (TKI). In this period, hema-
tological response(HR) was observed in 99.2% of the patients, cytogenetic response (CR) was observed in 88.7% of the patients (47 
of 53), and molecular response (MR) was observed in 75% of the patients. Clinicians had a tendency to prefer generic molecules in 
each sequent visit, and this switch rate was statistically significant (p< 0.001). 11 patients, who were using original molecules during 
all cohorts, switched to second generation TKI. On the other hand, only one patient, who was using generic molecules, switched to 
second generation TKI. Our paper may help to clarify the doubts about the efficacy of generic IM compared to original molecule. In 
our study we did not find any significant difference in HR, CR, and MR for original and generic drugs in each visit. Herein, we find low 
rates of need to switch to second generation TKIs with generic IM and no difference in treatment responses between generic and 
original molecules that confirms the non-inferiority of generic TKIs over original molecules.
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INTRODUCTION
Unsustainable drug prices in chronic myeloid leu-
kemia (CML) and cancer may be causing harm 
to patients. Advocating for lower drug prices is a 
necessity to save the lives of patients who cannot 
afford them.1 The patent date of imatinib mesylate 
(IM) in USA has just expired in January 2015. Pat-
ent expiration dates for IM may be different in dif-
ferent countries/regions. For example in Canada 
and Europe generic IM has been approved for CML 
recently.2 However in Turkey, generic IM prepa-
rations are currently present. In Turkey, between 
original and generic molecules of TKI’s there is 
a price difference because of the reimbursement 
policy. Thus, if a patient prefers original molecule, 
it means that the price difference has to be paid 
from the patient’s own personal budget. The ma-
jor concern for generic IM is its efficacy over the 
original drug, Glivec or Gleevec, although actually 
generics were shown to be bioequivalent in many 
basic studies.2 Elucidation of the non-inferiority 
of generic imatinib over the original molecule is 
important for effective clinical decision making 
in CML.3 The aim of this multi-center study is to 
assess the efficacy of generic IM over Glivec in 
terms of hematological, cytogenetic, and molecu-
lar responses in CML. 
PATIENTS AND METHODS
This work is designed as a multicenter retrospec-
tive study. The data of 120 CML patients who were 
treated with generic or original form of IM, were 
obtained from six different hematology clinics in 
Turkey between the years of 2009-2014 and ana-
lyzed retrospectively. Ethical approval has been 
obtained from the Ethics Committee of Hacettepe 
Medical School. All of the ethical considerations 
had been strictly followed in accordance with the 
Helsinki declaration. The patients were evaluated 
at 4 different time points for the change of medica-
tion and efficacy of treatment in each center. The 
data of age, gender, type and dose of treatment, 
adverse effects of the treatment, smoking history, 
ECOG performance, the stage of CML at diagno-
sis, cytogenetic and molecular remissions and bone 
marrow transplantation treatment were obtained. 
IM response was evaluated with criteria recom-
mended by European LeukemiaNet.4 Molecular 
response (MR) was decided with BCR-ABL1 gene 
transcript ratio that is reported as International 
Scale (IS). Complete hematologic response (CHR) 
was accepted as white blood cells <10x109 /L, ba-
sophils <5%, no myelocytes, promyelocytes, mye-
loblasts in the differential, platelet count <450x109 
/L and non-palpable spleen. Complete cytogenetic 
response (CCyR) was accepted as no Ph meta-
phases in cytogenetic analysis. Major molecular 
ÖZET
Jenerik İmatinib Mesilat KML’nin Klinik Yönetiminde Orijinal Glivec Kadar Etkilidir
Kronik myeloid lösemi (KML)’de ve diğer kanserlerde sürdürülemez ilaç fiyatları hastalara zarar verebilir.Biz bu çok merkezli 
çalışmada,KML’de jenerik imatinib mesilat (IM) ile Glivec’i hematolojik,sitogenetik ve moleküler yanıt açısından kıyaslamayı amaçladık.
IM’ın jenerik ya da original formu ile 2009-2014 yılları arasında Türkiye’deki 6 değişik hematoloji kliniğinde tedavi edilen 120 KML 
hastasının verileri geriye dönük olarak araştırıldı. İlk incelemede,orijinal molekül kullanan yalnızca bir hastanın ikinci jenerasyon tirozin 
kinaz inhibitörü (TKI)’ne geçtiği anlaşıldı. Bu periyodda,hastaların %99.2’sinde hematolojik yanıt (HR),%88.7’sinde(53 hastanın 47’si) 
sitogenetik yanıt (CR) ve %75’inde moleküler yanıt (MR)saptandı.Klinisyenlerin her vizit sonrası artan oranda jenerik moleküle geçme 
eğilimleri gözlendi ve bu jenerik ilaca geçme oranı istatistiksel olarak anlamlıydı(p< 0.001).Tüm kohortlarda, orijinal molekül kullanan 
11 hastanın ilacı ikinci jenerasyon TKI’a değiştirildi. Diğer yandan, jenerik molekül kullanan sadece bir hastanın ilacı ikinci jenrasyon 
TKI’a değiştirildi.Bu çalışma,jenerik IM’ın orijinal molekülle kıyaslanan etkinliği hakkındaki şüpheleri gidermeye yardımcı olabilir.Bizim 
çalışmamızda,orijinal ve jenerik ilaçlar arasında her vizitte tespit edilen HR,CR ve MR oranlarında farklılık saptanmamştır.Bu çalışmada 
jenerik IM kullanan hastalarda ikinci jenerasyon TKI’lerine geçme ihtiyacı düşük sıklıkta saptanmış olup aynı zamanda jenerik ve orijinal 
moleküller arasında tedavi yanıtı açısından farklılık saptanmamıştır.Sonuç olarak, bizim çalışmamızdaki bulgular jenerik TKI’lerinin orijinal 
molekül ile kıyaslandığında hiçbir eksik yönlerinin olmadığını desteklemektedir.
Anahtar Kelimeler: Jenerik, İmatinib, Glivec, Kronik Miyeloid Lösemi
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response is accepted as a BCR-ABL1 expression 
of ≤0.1% on the international scale. Categorical 
and continuous data were compared by the Chi-
square (or Fisher’s Exact test if required by sample 
size) and Independent-samples T-test, respectively. 
Bivariate correlation analysis for categorical vari-
ables was done by Spearman’s correlation analysis. 
Statistical Packages for the Social Sciences v17.0 
(SPSS Inc., Chicago, IL) software was used for sta-
tistical analyses.
RESULTS
There were 68 female and 52 male participants in 
the study. There was no difference in gender dis-
tribution of the cases between study centers. All 
of the patients were in chronic phase of CML at 
diagnosis. The median age of the participants were 
53 (21-81). The number of patients in each ECOG 
performance score were 70/32/7/3/0 for ECOG 
scores of 0/1/2/3/4 respectively. 8 patients’ ECOG 
score was unknown. At the onset of the study 104 
(86.7%) patients were using original imatinib 
whereas 16 (13.3%) patients were using generic 
imatinib molecules. The percentages of generic 
imatinib molecule usage in first, second, third and 
fourth visit were 13.3%, 20.8%, 41.7% and 43.3%, 
respectively. The mean period between each evalu-
ation was 9 months. Initial evaluation revealed that 
only one patient who was using original molecule 
switched to second generation TKI.  In this peri-
od, hematological response (HR) was observed in 
99.2% of the patients, cytogenetic response (CR) 
was observed in 88.7% of the patients (47 of 53), 
and molecular response (MR) was observed in 
75% of the patients. For each evaluation, the ra-
tio of drugs that were preferred by the clinicians 
is shown in Figure 1. According to Figure 1, clini-
cians had a tendency to prefer generic molecules in 
each sequent visit, and this switch rate was statisti-
cally significant (p<0.001). The rates of switching 
from original molecule to generic molecule, from 
original molecule to second generation TKI, and 
from generic molecule to second generation TKI 
are shown in Table 1. Accordingly, 11 patients, 
who were using original molecules during all co-
horts, switched to second generation TKI. On the 
other hand, only one patient, who was using ge-
neric molecules, switched to second generation 
TKI (Table 1). Response to treatment is shown in 
Figure 1. The ratio of drugs that were preferred by the clinicians for each evaluation.
Sec. Gen. TKI= Second Generation TKI
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Figure 2. The ratio of CML treatment responses at 
the four evaluation points including hematologi-
cal, cytogenetic, molecular response is shown in 
Figure 2. There was no statistical significant dif-
ference between original and generic molecules in 
terms of hematological, cytogenetic and molecular 
responses (Table 2).
DISCUSSION
In the literature there are studies that report the 
price difference between drugs are so important 
that it could be the only reason for changing the 
treatment with generic TKIs.5 Without consider-
ing the health care budget and pharmacoeconomy, 
it is not realistic to manage the treatment of CML 
since the economy is directly related with acces-
sibility of drug for patients and penetration of drug 
Figure 2. The ratio of CML treatment responses at the four evaluation points. 
(HR= hematological response, CR= cytogenetic response, MR= molecular response)
Table 1. The rates of switching from original molecule to generic molecule, from original molecule to second generation TKI, and 
from generic molecule to second generation TKI.
   Original to Second Generic to Second
 Original to Generic Generation TKI  Generation TKI
 n % n % n %
First Visit 1/103 1.0 - - - -
Second Visit 12/103 11.6 1/103 1.0 1/17 5.9
Third Visit 28/91 30.8 5/91 5.5 - -
Fourth Visit 28/56 50.0 5/56 8.9 - -
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to country. By looking this point of view, generic 
TKIs are very important for sustainability of the 
treatment and offer large amounts of health care 
budget savings.6 In a recent paper, it is stated that 
the patent of Glivec will expire in the near future in 
many countries and already generics have resulted 
in cost savings in countries which generic TKIs are 
in the market.7 The necessity to argue the cancer 
drug prices for finding solutions in order to reduce 
them, was stated in literature. Also it is stated that 
in CML drug prices should not exceed values that 
harm patients and societies.8 Because of ongoing 
debates about the efficacy of generic TKIs, some 
CML patients in Turkey who choose to continue 
with original molecule still have to pay the price 
difference individually. This may led to problems 
with the continuation of treatment as well as other 
social problems. Patient’s economic problems and 
healthcare policy could be the reasons of this ten-
dency in medium/low income countries. In a recent 
paper, it is reported that the potential cost savings 
and clinical benefits of generic IM depends on not 
only physicians but also market forces, third-party 
payer and regulatory authority behavior.9 Not only 
the drug prices but also the efficacy and side effects 
of generic TKIs are concerned. There are several 
studies that reported generic TKIs are also well 
tolerated and could be safely used.5 Conflicting 
data about generic TKIs efficacy and side-effects 
comes from relatively small number of patient co-
horts and this issue have been criticized in a re-
cently published paper.10  In the literature, there 
are some studies indicating the non-inferiority of 
generic TKIs in comparison to the original mole-
cule.11-13 However, there are different reports about 
generic TKIs which make clinicians to hesitate to 
switch to generic form. In the literature, some au-
thors suggested that original molecule is superior 
to generics.14,15 In a study which was conducted 
with 30 patients, generic TKI was used as first line 
therapy and resulted with 90% CHR and 46.7% 
molecular response rate.16 On the other hand, a 
Table 2. There was no statistical significant difference between original and generic molecules in terms of hematological, cytoge-
netic and molecular responses.
 Original TKI Generic TKI P value
HR1  99.0% 100.0% 0.683
CR1  89.3% 85.7% 0.775
MR1  76.3% 62.5% 0.391
HR2  98.9% 100.0% 0.584
CR2  97.7% 88.8% 0.197
MR2 90.5% 76.4% 0.109
HR3 100.0% 96.4% 0.154
CR3 96.9% 94.7% 0.687
MR3 97.6% 88.8% 0.102
HR4 100.0% 100.0% -------
CR4 95.6% 91.3% 0.550
MR4 93.9% 86.5% 0.280
(TKI= tyrosine kinase inhibitor, HR= hematological response, CR= cytogenetic response, MR= molecular response) (Numbers next 
to abbreviations refer to evaluation points)
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study with 126 patients resulted with lost in 33% 
CHR after changing the treatment to generics.17 
One of the clinical limitation of the reports which 
suggest generic TKIs are inferior that these studies 
involve relatively small number of cases or they 
are just case reports.18,19 Moreover, some of those 
studies were financially supported by pharmaceuti-
cal companies.18,19,20 Furthermore it is also unclear 
whether the generic IM which was used in these 
studies was bioequivalent or not.21 Likewise, there 
are speculations about the different crystal forms 
of IM may affect its clinical efficacy. However in 
literature there are no reports of different clinical 
efficacy related to polymorphism of IM.2 Our pa-
per may help to clarify the doubts about the effi-
cacy of generic IM compared to original molecule. 
As indicated in Figure 1, there is a tendency to use 
generic molecules in our country. In CML, the in-
dications for switching the treatment to the second 
generation TKIs are clearly stated in the litera-
ture.22 In our study, the data in Table 1 confirms the 
efficacy of generic TKIs because of the low rates 
of need to switch to second generation TKIs during 
treatment. Our study contributes to literature by the 
data of six different centers from Turkey. Moreo-
ver, in our study we did not find any significant 
difference in HR, CR, and MR for original and ge-
neric drugs in each visit. In an editorial paper it is 
stated that, theoretically retrospective studies have 
limitations in different manners which confirms 
actually there is a need for a Phase IV study that 
compares generic TKIs with original forms by the 
manner of efficacy and safety. However unfortu-
nately, it is very unlikely for this kind of study will 
be supported by the pharmaceutical companies. 
Therefore well-designed large-scale retrospective 
studies which patients diagnosed and followed 
with standard care of practice is the best choice to 
get reliable information about generic TKIs until 
long-term solid prospective data are available.6 
From this point of view our study is important as it 
is a multi-center study which includes the clinical 
follow-ups of the CML patients.
Conclusion: The findings of our study indicated 
that generic IM is as effective as original Glivec 
in the clinical management of CML. Although 
this data should be confirmed especially with pro-
spective studies, there is a huge benefit to patients 
as well as policy makers if the non-inferiority of 
generic molecules is evident. To conclude, in this 
study we find low rates of need to switch to second 
generation TKIs with generic IM and no difference 
in treatment responses between generic and origi-
nal molecules that confirms the non-inferiority of 
generic TKIs over original molecules.
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